COMP <GO>
CLYM vs GERN // EV/EBITDA & P/E VALUATION
Climb Bio Inc. (NASDAQ) VS. Geron Corporation (NASDAQ) • 15-METRIC TALLY: CLYM 3
— GERN 1
■ METRIC PARITY
LAST: $9.74 (-4.98%) • MKT CAP: $588.7M
valuation
—
LAST: $0.93 (+3.88%) • MKT CAP: $574.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLYM VS. GERN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLYM | GERN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -20.20% | -14.80 | GERN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.19% | -18.27% | +9.08 | CLYM | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.2 | 27.4 | +16.80 | CLYM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $588.7M | $574.6M | $14.1M | CLYM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLYM REV | GERN REV | CLYM GROSS % | GERN GROSS % | CLYM FCF | GERN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $190.1M | $192.0M | — | — | -$54.5M | -$111.0M |
| FY 2024 | $229.7M | $486.4M | — | — | -$15.6M | -$219.3M |
| FY 2023 | $112.8M | $237.0K | — | — | -$20.6M | -$167.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLYM // BETA —
GERN // BETA —